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Abstract
Background: Inflammation in the airways and lung parenchyma underlies fixed airway obstruction
in chronic obstructive pulmonary disease. The exact role of smoking as promoting factor of
inflammation in chronic obstructive pulmonary disease is not clear, partly because studies often do
not distinguish between current and ex-smokers.
Methods: We investigated airway inflammation in sputum and bronchial biopsies of 34 smokers
with chronic obstructive pulmonary disease (9 Global initiative for Chronic Obstructive Lung
Disease stage 0, 9 stage I, 10 stage II and 6 stage III) and 26 asymptomatic smokers, and its
relationship with past and present smoking habits and airway obstruction.
Results: Neutrophil percentage, interleukin-8 and eosinophilic-cationic-protein levels in sputum
were higher in chronic obstructive pulmonary disease (stage I-III) than asymptomatic smokers.
Inflammatory cell numbers in bronchial biopsies were similar in both groups. Current smoking
correlated positively with macrophages: in bronchial biopsies in both groups, and in sputum in
chronic obstructive pulmonary disease. Pack-years smoking correlated positively with biopsy
macrophages only in chronic obstructive pulmonary disease.
Conclusion:  Inflammatory effects of current smoking may mask the underlying ongoing
inflammatory process pertinent to chronic obstructive pulmonary disease. This may have
implications for future studies, which should avoid including mixed populations of smokers and ex-
smokers.
Background
Chronic obstructive pulmonary disease (COPD) is one of
the most important causes of death and its prevalence is
still increasing [1]. The major risk factor in the develop-
ment and progression of COPD is cigarette smoking.
COPD is characterised by fixed airway obstruction and
respiratory symptoms, i.e. chronic cough, sputum produc-
tion and dyspnoea. COPD patients have, just like so called
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healthy smokers, an inflammatory reaction involving the
entire tracheobronchial tree [2,3].
As compared to healthy non-smokers the degree of airway
inflammation seems higher in COPD patients. For exam-
ple, higher numbers of CD8 positive T-cells, macro-
phages, neutrophils, and mast cells, both in central and
peripheral airways have been found in COPD patients,
irrespective whether these patients were current smokers
or ex-smokers [4-10]. In addition, the percentage of neu-
trophils and IL-8 levels in sputum and broncho-alveolar
lavage of COPD patients were higher [7,11-16]. As com-
pared to healthy smokers, the differences with COPD
patients are less clear cut. For example, higher numbers of
neutrophils, macrophages and CD8 positive T-cells in the
peripheral airways of COPD patients were found as com-
pared to smokers [10,17-19], whereas others did not
[10,19,20]. Two studies showed a higher percentage of
neutrophils and higher IL-8 levels in broncho-alveolar
lavage of COPD patients [13,21], whereas Linden et al.
found no differences [7]. A few studies showed higher
numbers of neutrophils [22], CD3, CD4[23] CD8 positive
T-cells [23,24] in bronchial biopsies, whereas other stud-
ies found no differences in neutrophils [24], CD3, CD4
[22,24] and CD8 positive T-cels [22], macrophages, eosi-
nophils and mast cells [22,24]. In conclusion, COPD
patients have a higher degree of airway inflammation
compared to non-smokers, however it remains unclear
whether this is also true comparing COPD patients with
so called healthy smokers.
Definite conclusions about the exact role of cigarette
smoking in COPD are difficult to draw for a number of
reasons. First, most studies investigated smokers com-
bined with ex-smokers. Second, many studies investigated
COPD patients combined with patients with chronic
bronchitis. Third, many studies investigated only one
aspect of inflammation, or only one compartment (spu-
tum, broncho-alveolar lavage, bronchial biopsies, periph-
eral airways), which may be insufficient to obtain a full
view. Fourth, remodelling in COPD may itself generate
and maintain an inflammatory process, independent of
cigarette smoking [25].
In order to elucidate the role of smoking on inflammation
in COPD we have investigated airway inflammation in
sputum and bronchial biopsies of asymptomatic smokers
and smokers with COPD. Furthermore, we assessed
whether airway inflammation is related to the number of
cigarettes smoked per day, to pack-years smoking and to
severity of airway obstruction.
Methods
Subjects
Subjects were recruited from the pulmonary outpatient
clinic of the Groningen University Hospital and by adver-
tisements in local newspapers. 34 smokers with COPD
and 26 smokers without COPD were included according
to the ERS criteria [26]. Smokers with COPD had chronic
cough and sputum production for at least 3 months for 2
successive years, and an forced expiratory volume in one
second (FEV1)/ vital capacity (VC) ≤  88% of predicted for
males and ≤  89% of predicted for females. Asymptomatic
smokers without COPD had no chronic respiratory symp-
toms, and FEV1/VC >88% of predicted for males and
>89% of predicted for females and an FEV1 >85% of pre-
dicted. To detect respiratory symptoms to delineate the
group of symptomatic smokers without COPD we used
the questions about respiratory symptoms and smoking
from the Dutch version of the British Medical Research
Council's standardised questionnaire [27]. These data
were collected by interviewing the participants at the first
visit. All participants had to meet the following criteria:
age between 45–75 years, minimum of 10 pack-years
smoking, actual smoking ≥  10 cigarettes per day, reversi-
bility to salbutamol < 9% of the predicted FEV1, no use of
inhaled or oral corticosteroids in the previous 6 months,
no atopy (no positive skin prick test for 10 common aer-
oallergens and serum total IgE < 200 IU), no respiratory
tract infection 1 month prior to the study. After inclusion,
subjects were categorized according to the Global Initia-
tive for Chronic Obstructive Lung Disease, GOLD stage 0-
IV [28]. GOLD stage 0 (symptomatic smokers): 'at risk'
with normal spirometry but chronic symptoms (cough,
sputum production); GOLD stages I-IV: FEV1/FVC post
bronchodilator (post BD) < 70% and GOLD stage I: FEV1
post BD ≥  80% predicted; GOLD stage II: 50% ≤  FEV1 post
BD < 80% predicted; GOLD stage III: 30% ≤  FEV1 post BD
<50% predicted and GOLD stage IV: 30% ≤  FEV1 post BD
or FEV1<50% predicted plus respiratory failure. Current
smoking was confirmed by urinary cotinine levels > 25
ng/ml. Before each measurement subjects were asked not
to use long or short-acting β 2 agonists and/or ipratropium
at least 12 hours before the test. The local medical ethics
committee approved the study protocol and all subjects
gave their written informed consent.
Study Design
All subjects visited the hospital on 5 separate days, at least
one week apart. Lung function tests (flow-volume curves,
reversibility, airway conductance), airway hyperrespon-
siveness (AHR) to methacholine and to adenosine-5'-
monophosphate (AMP), and sputum induction (twice)
were performed and all subjects underwent
bronchoscopy.Respiratory Research 2005, 6:38 http://respiratory-research.com/content/6/1/38
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Lung Function
Lung function (FEV1, FEV1/VC) was measured using dry
wedge spirometry (Masterscope, Jaeger, Breda, The Neth-
erlands) according to standardized guidelines [29]. Spe-
cific airway conductance (sGaw) was measured by body
plethysmography (Masterscope, Jaeger, Breda, The Neth-
erlands). Provocation tests were performed with a 2-
minute tidal breathing method adapted from Cockcroft
and co-workers [30]. After an initial nebulised saline
(0.9%) challenge, subjects inhaled doubling concentra-
tions, ranging from 0.038 to 39.2 mg/ml of metha-
choline-bromide (Sigma Chemical Co. St Louis, MO) and
from 0.04 to 320 mg/ml of AMP (Sigma Chemical Co. St
Louis, MO) at 5-minute intervals. Tests were terminated
when FEV1 had fallen 20% or more from its baseline value
(PC20).
Sputum Induction and Sputum Processing
Sputum was induced by inhalation of hypertonic saline
aerosol and processed as described previously [31]. Briefly
15 minutes after salbutamol (400 µg) inhalation, hyper-
tonic saline (3%, 4% and 5% w/v) was nebulised and
inhaled for each concentration over a period of 7 minutes.
Whole sputum samples were processed within 2 hours
after termination of the induction. Two sputum cytospin
slides were stained with May-Grünwald-Giemsa for differ-
ential cell counts. Counting of 600 non-squamous cells in
a blinded way by one technician (B.R.). Sputum samples
containing > 80% of squamous cells were excluded from
analysis as indication of poor cytospin quality. Inter-
leukin 8 (IL-8) concentration was measured using ELISA
(CLB, Amsterdam, the Netherlands) and eosinophil cati-
onic protein (ECP) concentration by a fluorenzyme
immunoassay (ImmunoCAP ECP, Pharmacia, Uppsala,
Sweden).
Bronchoscopy and biopsy processing
Subjects were not allowed to drink or eat at least 4 hours
prior to the bronchoscopy. Smoking was not allowed
before the bronchoscopy. On arrival, FEV1 was measured
before and 15 minutes after 400 µg salbutamol. Hereafter
subjects gargled with 5 ml of 2% lidocaine and had 2%
lidocaine sprayed on the posterior pharynx, dripped onto
the vocal cords and into the trachea, with a maximum
dose of 3 mg/kg lidocaine. A flexible fiberoptic broncho-
scope (Olympus B1 IT10, Olympus Optical, Tokyo,
Japan) was introduced and preferably 6 bronchial biop-
sies were taken from the subcarinae of the right middle or
lower lobe using a fenestrated cup forceps (Olympus FB-
21C, Olympus Optical Tokyo, Japan) [32]. Biopsies were
collected into sterile PBS on ice. Two biopsies were
directly embedded in Tissue Tek (Bayer Corporation,
Elkhart, Indiana, USA), snap-frozen in liquid isopentane
and stored at -80°C, 4 biopsies were fixed in 4% parafor-
maldehyde, processed and embedded in paraffin.
Serial sections were cut from the paraffin biopsies with a
thickness of 4 µm and stored at room temperature. Selec-
tion of morphological optimal tissue was based on a
hematoxylin and eosin stained slide. Tissue slides were
deparaffinised with xylene (15 min) and dehydrated
before staining. Immunohistochemical staining was per-
formed with monoclonal antibodies against: CD3
(A0452, DAKO, Copenhagen, Denmark) CD4 (CD4-368,
Novacastra, UK), CD8 (M7103, DAKO), B cells (CD20
L26, M0755, DAKO), mast cell tryptase (AA1, M7052,
DAKO), neutrophil elastase (NP57, M0752, DAKO), mac-
rophages (CD68, M0814, DAKO) and secreted form of
eosinophilic cationic protein EG2 (Pharmacia Diagnos-
tics, Sweden). Negative controls were obtained by omis-
sion of the primary antibody. Slides were pre-treated with
1 mM EDTA buffer pH = 8 (CD4, CD8), 0.1 mM tris-HCL
buffer pH = 9.0 (CD20) in the microwave for 8 or 30 min-
utes respectively or with 1% protease for 30 minutes at
room temperature (CD68, NP57, AA1, EG2). CD3 slides
were incubated overnight at 80°C with tris/HCL buffer
pH = 9.0. All stainings were performed in an automated
system using the Dako Autostainer (DAKO, Copenhagen,
Denmark), except for CD4 that was done manually.
The dilutions used were: CD3 1:100; CD4 1:25; CD8
1:100; CD68 1:50; EG2 1:200; NE 1:200; AA1 1:100;
CD20 1:400. As detection system we used labelled strepta-
vidin-biotin (LSAB+, K0690, DAKO, Copenhagen, Den-
mark) except for CD4 where the Envision system (K5007,
DAKO, Copenhagen, Denmark) was used. 3-amino-9-
Ethyl Carbazole (AEC) (K3469, DAKO, Copenhagen,
Denmark), or Nova Red (SK4800, Vector, USA) for CD4,
was used as a chromogen (substrate) giving a reddish-
brown reaction product. Hydrogen peroxide was used for
blocking endogenous peroxidase and haematoxylin was
used as a counterstain. For each antigen, all slides were
stained simultaneously.
For each immunohistochemical staining 2 sections of 2
different bronchial biopsies were quantified by computer-
assisted image analysis at magnification of 200× (Qwin,
Leica Microsystems Imaging Solutions Ltd, Cambridge,
UK). Automated image analysis to quantify immunopos-
itivity was performed using the next algorithm: first the
intensity of the positive area (cells) was appointed in each
biopsy by the observer, followed by the intensity of the
total area of the biopsy, based on the red-green-blue
(RGB) color model [33,34]. After this, all images of the
biopsy were analyzed. Excluded were epithelium, submu-
cosal glands, airway smooth muscle tissue and damaged
tissue. Afterwards, the algorithm determined the
immuno-positive area and the measured area of the
biopsy, leading to the percentage positive area per biopsy.
A positive area was at least 11.8 µm2, to exclude false pos-
itive areas. In this manner, the total positive area and theRespiratory Research 2005, 6:38 http://respiratory-research.com/content/6/1/38
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total measurable area of the biopsy were quantified and
the percentage positive area per biopsy was calculated.
The smallest evaluable area per section (after exclusion of
epithelium, submucosal glands, airway smooth muscles
and damaged tissue) was 0.4 mm2. The mean percentage
positive area of two biopsies was used. Measurements
were performed in a blinded way by 2 observers (B.R. and
B.W.).
Data analysis
Analyses were performed using SPSS for Windows 10.0
(SPSS Inc., Chicago, IL). Values of p < 0.05 were consid-
ered statistically significant. Clinical data were expressed
in means (± SD) or geometric means (minimum-maxi-
mum); inflammatory data were expressed in medians
(minimum-maximum). Differences between asympto-
matic smokers, symptomatic smokers (GOLD 0) and
smokers with COPD (GOLD stage I, II and III) were ana-
lysed using the Kruskall-Wallis test, a non-parametric
equivalent to one-way ANOVA. Only, when the Kruskall-
Wallis test was significant the Mann Whitney U test was
used to analyse the differences between the 3 groups. Dif-
ferences between GOLD stages 0, I, II, and III were ana-
lysed using the Kruskall-Wallis test, when this test was
significant the Mann Whitney U test was used to analyse
the differences between the different GOLD stages.
Correlations between smoking characteristics and lung
function parameters were calculated with Pearson correla-
tion test. Correlations between inflammatory cells and
mediators in sputum and/or bronchial biopsies and
smoking characteristics or lung function parameters were
calculated with Spearman's rank correlation test. The sub-
jects with GOLD stages I-III were used to investigate the
correlations in COPD patients.
Results
Asymptomatic smokers versus smokers with GOLD stage 0-
III
The 34 smokers with COPD were categorised into GOLD
stage 0 'symptomatic smokers' (n = 9), GOLD stage I (n =
9), stage II (n = 10) and stage III (n = 6); none of the
patients fulfilled the criteria for GOLD stage IV. The clini-
cal characteristics of all subjects are presented in (see
Additional file 1). Symptomatic smokers (GOLD stage 0)
had significantly decreased lung function and more severe
hyperresponsiveness to AMP than asymptomatic smokers
had. COPD patients in GOLD stages I-III were older, had
significantly more pack-years smoking, lower airway con-
ductance and more severe hyperresponsiveness to AMP
and methacholine than asymptomatic and symptomatic
(GOLD 0) smokers.
Sputum
Two asymptomatic smokers could not produce sputum.
The median (range) percentage non-squamous cells was
94 (75–99)% in COPD patients and 88 (64–99)% in
asymptomatic smokers (table 1). Symptomatic smokers
(GOLD 0) had higher percentage of sputum neutrophils
than asymptomatic smokers. Smokers with COPD
(GOLD stage I-III) had higher percentage of neutrophils,
IL-8 and ECP levels in sputum than asymptomatic smok-
ers, and higher IL-8 levels in sputum than symptomatic
smokers. The percentage of macrophages was lower (table
1). In the separate GOLD stages, GOLD stage II had a
higher percentage of sputum neutrophils compared with
the asymptomatic smokers (70% and 60% respectively)
and higher IL-8 and ECP levels in sputum than GOLD
stage 0 and I (21.4 ng/ml versus 8.7 and 8.5 ng/ml respec-
tively, and 291 µg/L versus 120 and 99 µg/L respectively).
GOLD stage III had higher levels of IL-8 than GOLD stage
0 (27.7 ng/ml and 8.7 ng/ml respectively) and lower ECP
levels than GOLD stage II (87 µ/L versus 291 µg/L).
Bronchial biopsies
Bronchial biopsies could not be collected or were of insuf-
ficient quality in 2 asymptomatic smokers, in 1 subject
GOLD stage 0, and in 6 COPD patients. The percentage
positive area of inflammatory cells in bronchial biopsies
(CD3, CD4, CD8, CD20, neutrophils, macrophages, eosi-
nophils and mast cells) did not differ between COPD
(GOLD I-III), symptomatic smokers (GOLD 0) and
asymptomatic smokers (table 2). Only COPD patients
with GOLD stage II had a higher percentage positive CD3
area than asymptomatic smokers (1.84 (0.24–9.24) and
0.76 (0.17–2.4) respectively).
Correlations of lung function with smoking and airway 
inflammation
FEV1 post BD (% predicted) correlated negatively with the
number of pack-years smoking (r = -0.51, p = 0.03) in
COPD, but not significantly with the number of cigarettes
smoked per day.
FEV1 post BD correlated negatively with IL-8 levels in spu-
tum and positively with macrophages in sputum and mast
cells in bronchial biopsies of patients with COPD (table
3). The latter correlation was mainly caused by 4 patients
with low mast cell positive areas. In asymptomatic smok-
ers, no significant correlations were found between lung
function and airway inflammation (table 3).
AHR did not correlate with number of cigarettes smoked
per day, number of pack-years smoking or airway inflam-
mation in sputum or bronchial biopsies in both asympto-
matic smokers and COPD patients (data partially
presented and discussed earlier: Willemse et al, [35]).Respiratory Research 2005, 6:38 http://respiratory-research.com/content/6/1/38
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Correlations of current smoking with airway inflammation
The number of cigarettes smoked per day correlated nega-
tively with neutrophils and positively with macrophages
in sputum, which was significant in COPD (table 3, figure
1). The number of cigarettes smoked per day correlated
positively with macrophages in bronchial biopsies, in
both groups (table 3, figure 2). In asymptomatic smokers,
the number of cigarettes per day correlated negatively
with the number and percentage of eosinophils in spu-
tum. In COPD the number of cigarettes smoked per day
correlated negatively with eosinophil area in bronchial
biopsies (table 3).
Correlations of pack-years smoking with airway 
inflammation
In COPD patients pack-years smoking was positively cor-
related with the macrophage percentage positive area
(table 3). Otherwise no significant correlations were
found.
Table 1: Sputum inflammation in smokers with COPD, symptomatic smokers and asymptomatic smokers
COPD Symptomatic smokers Asymptomatic smokers
GOLD I-III GOLD 0
Sputum, n 25 9 24
Volume, ml 4.1 (0.7–14.3) 3.1 (0.3–10.0) 2.3 (0.6–10.8)*
Total cells, 106 6.7 (1.4–54.5) 4.1 (1.1–15.3) 3.5 (0.2–23)*
Cell conc., 103/ml 1507 (484–9620) 2134 (534–4146) 1445 (303–4592)
Nonsquamous cells, % 94 (75–99.7) 92 (81–96) 88 (64–99.5)
Eosinophils, 103/ml 15 (0–106) 20 (0–135) 13 (0–235)
% 1.4 (0–4.0) 1.8 (0–4.1) 0.8 (0–12.6)
Neutrophils, 103/ml 870 (235–7608) 1575 (434–2558) 661 (164–2856)
% 72.6 (45–89) 66 (39–81) 60.1 (31.5–92.6)* †
Macrophages, 103/ml 407 (89–2615) 535 (89–2422) 568 (22–1488)
% 25.4 (8.2–52.7) 28.7 (16.6–58.4) 36 (6.5–62.4)*
Lymphocytes, 103/ml 14 (0–77) 15 (0–62) 11 (1–161)
% 0.8 (0.1–4) 0.8 (0.4–1.6) 0.7 (0.1–3.8)
Epithelial cells, 103/ml 10 (0–107) 0.4 (0–84) 10 (0–55)
% 0.5 (0–11) 0.5 (0–2.5) 0.8 (0–6.6)
Basophils, 103/ml 0 (0–4) 0 (0–12) 0 (0–8)
% 0 (0–0.1) 0 (0–0.3) 0 (0–0.3)
IL-8, ng/ml 16.8 (2.1–161)† 8.7 (0.1–25.7) 5.3 (0–25)*
ECP, µg/L 157 (32–2700) 119.8 (13.3–238) 66 (4.7–1282)*
Values expressed in median (range). Abbreviations: cell conc. = cell concentration; IL-8 = interleukin-8; ECP = eosinophilic cationic protein.
* p < 0.05 asymptomatic smokers versus total COPD (I-III), Mann-Whitney -U test, † p < 0.05 versus GOLD stage 0, Mann-Whitney-U test.
Table 2: Inflammation in bronchial biopsies from smokers with COPD and asymptomatic smokers
Total COPD Symptomatic smokers Asymptomatic smokers
GOLD I-III GOLD 0
Biopsies, n 19 8 24
CD3, %positive area 1.05 (0.2–9.24) 0.68 (0.19–1.7) 0.76 (0.17–2.4)
CD4, %positive area 0.041 (0.01–0.57) 0.073 (0–0.18) 0.04 (0–0.15)
CD8, %positive area 0.27 (0.03–2.55) 0.19 (0.02–1.53) 0.33 (0.3–1.25)
CD4/CD8 ratio 0.19 (0.1–4.4) 0.39 (0.04–1.2) 0.18 (0–0.91)
CD20, %positive area 0.003 (0–3.40) 0.003 (0–0.23) 0.005 (0–0.12)
NP57, %positive area 0.025 (0–0.13) 0.05 (0–0.23) 0.021 (0–0.36)
CD68, %positive area 0.035 (0–0.21) 0.056 (0–0.16) 0.041 (0–0.32)
EG2, %positive area 0.021 (0–0.31) 0.049 (0–0.15) 0.063 (0–0.59)
AA1, %positive area 0.15 (0.01–0.91) 0.22 (0–0.41) 0.22 (0.1–1.16)
Values expressed in median (range). Abbreviations: CD20 = B-cell marker, NP57 = neutrophil elastase, CD68 = macrophages, EG2 = eosinophils, 
AA1 = mast cell tryptase.Respiratory Research 2005, 6:38 http://respiratory-research.com/content/6/1/38
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Discussion
This study shows that asymptomatic smokers, sympto-
matic smokers (GOLD stage 0), and smoking patients
with COPD have a large overlap in inflammation as
assessed in sputum and airway wall biopsies. Patients
with stage GOLD I-III had a higher percentage of neu-
trophils, and higher ECP and IL-8 levels in sputum than
asymptomatic smokers, and higher IL-8 levels than symp-
tomatic smokers. In symptomatic smokers percentage
sputum neutrophils were higher than in asymptomatic
smokers.
Table 3: Spearman's rank correlations between current smoking and airway obstruction and airway inflammation.
COPD GOLD I-III (n = 19) Asymptomatic smokers (n = 26)
rho p-value rho p-value
Cigarettes/day
Neutrophils sputum, % -0.46 0.02 -0.24 NS
Macrophages sputum, % 0.44 0.027 0.35 0.095
Eosinophils sputum, % -0.19 NS -0.39 0.057
Eosinophils sputum, 106/ml -0.11 NS -0.44 0.029
CD68 biopsy, % pos. area 0.69 0.002 0.46 0.029
EG2 biopsy, % pos. area -0.79 0.001 0.02 NS
Pack-years smoking
CD68 biopsy, %pos. area 0.48 0.043 0.21 NS
FEV1 post BD, %pred.
Neutrophils sputum, % -0.31 NS 0.15 NS
Macrophages sputum, % 0.41 0.046 -0.22 NS
IL-8 sputum, ng/ml -0.54 0.007 0.15 NS
CD68 biopsy, %pos. area 0.33 NS 0.18 NS
AA1 biopsy, %pos. area 0.53 0.02 0.09 NS
CD68 = macrophages; EG2 = eosinophils; % pos. area = percentage positive area; FEV1 = forced expiratory volume in one second; post BD = post 
bronchodilator (15 minutes after 400 µg salbutamol); IL-8 = interleukin 8; AA1 = mast cells; NS = not significant
Spearman's rank correlation: Cigarettes smoked per day and  percentage of macrophages in biopsies Figure 2
Spearman's rank correlation: Cigarettes smoked per day and 
percentage of macrophages in biopsies. COPD (■ , ): 
rho = 0.69 p = 0.002 and asymptomatic smokers(, 
): rho = 0.46 p = 0.03. - - - - 
Spearman's rank correlation: Cigarettes smoked per day and  macrophages in induced sputum Figure 1
Spearman's rank correlation: Cigarettes smoked per day and 
macrophages in induced sputum. COPD (■ ,  ): rho = 
0.44 p = 0.03 and asymptomatic smokers(, ):  rho  = 
0.35 p = 0.1.
- - - - Respiratory Research 2005, 6:38 http://respiratory-research.com/content/6/1/38
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Whereas current smoking was associated with higher
numbers of inflammatory cells in both asymptomatic
smokers and COPD patients, pack-years smoking was
only associated with higher airway wall macrophages in
COPD and to the severity of airway obstruction. More
severe airway obstruction in its turn was associated with
lower percentage of sputum macrophages in smokers with
COPD. Thus, the small difference in airway inflammation
found between smokers with and without COPD may be
due to the interference of current cigarette smoking.
This study demonstrates that a higher number of daily
smoked cigarettes is associated with a higher percentage of
macrophages in bronchial biopsies and sputum, both in
smokers with COPD and asymptomatic smokers. In addi-
tion, eosinophils and neutrophils in sputum were nega-
tively correlated to current smoking. Only few studies
have provided data on correlations between airway
inflammation and current smoking since smokers and ex-
smokers were generally investigated together as one
group. Two studies reported a positive correlation
between neutrophils in bronchoalveolar lavage and the
number of cigarettes smoked per day when asymptomatic
smokers, chronic bronchitis patients and COPD patients
were analysed together [7,13]. One study in asympto-
matic smokers reported that the number of cigarettes
smoked per day correlated positively with macrophages
and IL-8 levels in bronchoalveolar lavage [36].
Macrophages in the central airways of smokers with and
without COPD may be a direct inflammatory reflection of
current smoking. On the other hand, it is not likely that
current smoking is the only factor responsible for the
accumulation of macrophages, since they are also
increased in bronchial biopsies of ex-smokers with COPD
[37]. Furthermore, we show that not only current smok-
ing but also a higher number of pack-years smoking is
associated with higher number of macrophages in COPD.
This suggests that effects of current smoking are superim-
posed upon the underlying macrophage infiltration,
which is part of the ongoing inflammatory process in
COPD. This is important to realise when investigating the
inflammatory and remodelling processes in smokers and
ex-smokers with or without COPD. We therefore strongly
suggest to avoid including mixed populations of smokers
and ex-smokers in future studies on inflammatory proc-
esses in COPD
Current smoking was negatively related to eosinophils,
i.e. the more cigarettes smoked per day the fewer eosi-
nophils were present in sputum of asymptomatic smokers
and in bronchial biopsies of patients with COPD. It may
be that smoking has an anti-inflammatory effect on eosi-
nophils or may influence cell kinetics. It has been sug-
gested that carbon monoxide (CO) present in cigarette
smoke has an anti-inflammatory potential [38,39], at
least with respect to certain cell types and/or subsets. The
extent and relevance of this supposed anti-inflammatory
effect in humans remains to be established, but in guinea
pigs it has been shown that acute cigarette smoke expo-
sure suppresses the number of eosinophils after 6, 12 and
24 hours [40]. This may indicate that even the cigarettes
smoked 24 hours before sputum induction or bronchos-
copy could have induced this inverse relationship
between current smoking and eosinophilic inflammation,
since our participants refrained from smoking for 8 hours
before the bronchoscopy. Nevertheless, it is well known
that repetitive smoking for several years causes extensive
damaging effects, indicating that the long-term overall
effects of cigarette smoke dominate the anti-inflammatory
effects.
Macrophages in bronchial biopsies of smokers with
COPD were positively associated with pack-years smok-
ing. No other relationships between pack-years smoking
and airway inflammation were found in our study. This is
in agreement with previous studies which either did not
find any correlations [41] or did not investigate this
[11,15,42]. Only Lams et al. [24] reported a positive cor-
relation between CD8+ cells in bronchial biopsies and
pack-years smoking and a negative correlation between
neutrophils in bronchial biopsies and pack-years smok-
ing, when all smokers (COPD and asymptomatic smok-
ers) were analysed. In broncho-alveolar lavage percentage
neutrophils was positively associated with pack-years
smoking when all smokers and ex-smokers with and with-
out COPD were analysed together [7,13].
One would expect that in COPD patients inflammatory
markers would be more related to pack-years smoking
instead of the number of cigarettes smoked per day. How-
ever, only macrophages in bronchial biopsies showed a
positive correlation with pack-years smoking whereas
macrophages, eosinophils and neutrophils were related to
the number of cigarettes smoked. This may indicate that
some of the inflammation due to cumulative smoke expo-
sition is overruled by inflammation caused by current
smoking. Neutrophils and eosinophils are "fast moving,
or transient" inflammatory cells, whereas macrophages
remain much longer in the lung tissue. This stresses the
importance of macrophages in the development and pro-
gression of COPD.
This study shows that the percentage of neutrophils in
sputum is higher in smokers with COPD (median 72.6%)
than in asymptomatic smokers (median 60.1%), espe-
cially in GOLD stage II. This is completely in line with
results of previous studies, which showed that smokers
with moderate to severe COPD had higher total cell num-
bers and percentages of neutrophils in sputum than
asymptomatic smokers [11,15,42]. Thus our findingRespiratory Research 2005, 6:38 http://respiratory-research.com/content/6/1/38
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suggests that this aspect of inflammation is associated
with disease severity.
In symptomatic smokers (GOLD stage 0) the percentage
of neutrophils in sputum was higher than in asympto-
matic smokers, but similar to COPD patients. This has not
been investigated in induced sputum before, however in
broncho-alveolar lavage neutrophils show the same pat-
tern [12]. No other differences were found in airway
inflammation between symptomatic smokers and asymp-
tomatic smokers. This is in contrast to the study of Sun et
al [43], who investigated smokers with chronic bronchitis
and found not only an increased number of neutrophils
in broncho-alveolar lavage, but also increased eosi-
nophils, mast-cells, CD4 positive and CD8 positive T cells
compared to "healthy" smokers. This suggests that
chronic bronchitis is better reflected by broncho-alveolar
lavage than by induced sputum or bronchial biopsies.
In the present study, IL-8 levels in sputum were signifi-
cantly higher in smokers with COPD than in asympto-
matic and symptomatic smokers. In addition, higher IL-8
levels strongly correlated with more severe airway obstruc-
tion in smokers with COPD. This is in line with the data
of Keatings et al. who showed that both IL-8 and percent-
age of neutrophils in sputum were increased in patients
with moderate COPD as compared to asymptomatic
smokers [15]. This may suggest that IL-8, a
chemoattractant of neutrophils and an activator of MMP-
9, plays a role in the development of airway obstruction.
Alternatively, this may reflect the airway obstruction
present.
Inflammatory cell density in bronchial biopsies did not
significantly differ between smokers with COPD (GOLD
I-III), asymptomatic smokers and symptomatic smokers.
Only CD3 percentage positive areas in bronchial biopsies
were higher in smokers with COPD stage II than in
asymptomatic smokers. In agreement with our findings,
other studies [24,41] investigating smokers with and
without COPD, found no differences in neutrophils, mac-
rophages, eosinophils, CD4 positive cells or CD4/CD8
ratio in bronchial biopsies. In contrast, one previous
study demonstrated a higher number of CD8+ cells in
smokers with predominantly moderate COPD compared
to asymptomatic smokers [24]. In addition, two other
studies demonstrated that CD3+ and CD8+ cell numbers
were lower and macrophages and neutrophils were higher
in smokers with severe COPD [22,41]. It may thus well be
that differences between smokers with and without
COPD become only apparent in case of severe COPD.
Unfortunately the number of patients with evaluable
biopsies was too small in our study population (n = 4) to
investigate whether this indeed is the case.
A factor that should be taken into consideration is the age
difference between the COPD patients and asymptomatic
smokers under study. Previous studies investigated
younger (mean age 35 years) asymptomatic smokers than
our participants (mean age 50 years) [11,15,42]. The com-
position of sputum may differ between older and younger
healthy subjects, as shown in bronchoalveolar lavage
where the number of total cells and neutrophils increase
with age [44]. Since we investigated COPD patients and
asymptomatic smokers of almost similar age, our data are
not hampered by age differences.
Conclusion
Smoking COPD patients with GOLD stage I-III had
almost similar airway wall and sputum inflammation as
asymptomatic and symptomatic smokers without airway
obstruction. Current smoking was associated with airway
inflammation in patients with COPD and in asympto-
matic smokers, whereas this was not the case for the
cumulative pack-years smoked. In contrast, cumulative
pack-years smoking was associated with the level of air-
way obstruction in COPD, suggesting that cumulative
smoking induces chronic inflammation with subsequent
sequelae of airway obstruction. Our results indicate that
inflammatory effects of current smoking may mask find-
ings of chronic inflammation in COPD, since numbers of
inflammatory cells in bronchial biopsies and sputum are
comparable in smokers with mild COPD and asympto-
matic smokers.
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